Mydecine Innovations Group has signed a five-year psychedelic research agreement with Johns Hopkins University School of Medicine.
The agreement between emerging biotech and life sciences company Mydecine and Johns Hopkins University School of Medicine (JHU) will allow for collaboration on numerous research initiatives in the coming years. The agreement aims to advance research on novel psychedelic therapies to treat mental health and addiction disorders.
Advancing psychedelic research
Mydecine Innovations Group develops and commercialises innovative solutions for treating mental health problems and enhancing vitality, and is building an R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. The company has exclusive access to a full cGMP certified pharmaceutical manufacturing facility, and is able to import, export, cultivate, extract, isolate, and analyse active mushroom compounds with full government approval through Health Canada.
The partnership with Johns Hopkins University School of Medicine will see the collaborative research led by professor of psychiatry and behavioural sciences at the University, Dr Matthew Johnson, PhD, who has extensive experience conducting clinical research related to the therapeutic use of psychedelics.
Mydecine CEO Josh Bartch commented: “We are excited to expand on the current work we are conducting with Dr Matt Johnson and his team at JHU in regards to smoking cessation to include numerous other projects over the next five years. The researchers at JHU have proven their incredible depth of knowledge in the field.”
“The long-term potential of this research agreement is captivating for us here at Mydecine,” said Mydecine CSO and co-founder, Rob Roscow. “It demonstrates our commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.”
Mydecine CMO, Dr Rakesh Jetly added: “Despite the recent attention to opiate and dependance on other illicit substances, we sometimes forget about the incredible burden that nicotine dependence has on our societies.
“According to the CDC, cigarette smoking is the leading cause of preventable disease and death in the United States, killing more than 480,000 Americans each year. Despite all the public education and dire warnings, cigarette smoking remains one of the most difficult addiction to treat and contributes to more deaths than all the other substances combined, making research like this vital.”
